PATENT CLAIM ANALYSIS

Application Number: 16374912
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-07
Patent Classification: ["514", "528000"]

Abstract:
Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Claim (Index 11):
A method of treating osteoarthritis, the method comprising\n administering to a subject affected by osteoarthritis an effective amount of Adelmidrol and hyaluronic acid or a salt thereof so as to increase endogenous levels of palmitoylethanolamide without inhibiting the activity of palmitoylethanolamide-degrading FAAH and NAAA enzymes in the subject, and thereby treating osteoarthritis in the subject, wherein the subject is a human being or animal.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.5641
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14378185', '14323673', '15603566', '14103463', '14536186']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.720128958787435
- 35 USC 102 Novelty (BERT): 0.4934343755729983
- Combined Prediction Score: 0.6974595004659914
- Mean Citation Score: 145.48307200000005
- Max Citation Score: 168.08438
- Similarity Product: 104.71863690165044

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test